
-
Krystal Biotech NASDAQ:KRYS Krystal Biotech, Inc. is a pivotal-stage gene therapy company leveraging its novel, redosable gene therapy platform and in-house manufacturing capabilities to develop therapies to treat serious rare diseases.
Location: 2100 Wharton St Ste 701, Pennsylvania, 15203, US | Website: www.krystalbio.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
3.899B
Cash
588.3M
Avg Qtr Burn
N/A
Short % of Float
13.14%
Insider Ownership
12.48%
Institutional Own.
-
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
VYJUVEKTM (B-VEC) (Topical Beremagene Geperpavec) Details Skin disease/disorder, Dystrophic epidermolysis bullosa, Epidermolysis bullosa | Approved Quarterly sales | |
KB301 Details Wrinkles | Phase 2 Initiation | |
KB105 Details Autosomal recessive congenital ichthyosis , Skin disease/disorder | Phase 1/2 Initiation | |
Ophthalmic B-VEC Details Dystrophic epidermolysis bullosa | Phase 1/2 Initiation | |
KB707 (IL-2 and IL-12) Details Solid tumor/s, Multiple tumors, Cancer | Phase 1 Data readout | |
KB408 Details Severe alpha-1 antitrypsin deficiency | Phase 1 Update | |
Inhaled KB707 Details Solid tumor/s, Lung Metastases, Cancer | Phase 1 Update | |
KB407 Details Cystic fibrosis | Phase 1 Update |